8-KEarnings & ResultsExhibits & Filings

ABBOTT LABORATORIES 8-K Report, Financial Results (Apr 22, 2015)

Filed April 22, 2015For Securities:ABT

Summary

This 8-K filing from Abbott Laboratories (ABT), dated April 22, 2015, primarily serves to report the company's first-quarter 2015 financial results. The filing incorporates by reference a press release (Exhibit 99.1) detailing these results. A key aspect highlighted is Abbott's use of non-GAAP financial measures, which exclude items like cost reduction initiatives, transaction-related costs, and tax expenses from one-time foreign earnings repatriation, as well as intangible amortization. The company states that these non-GAAP figures provide a clearer view of ongoing business performance and are used internally for assessment. Investors are advised to consider these non-GAAP measures alongside, but not as a substitute for, standard GAAP financial figures. While the specific financial figures are not detailed within the 8-K itself but rather in the referenced press release, the primary takeaway for investors is Abbott's approach to financial reporting, emphasizing adjusted metrics to show core operational strength. This approach aims to offer better visibility into the company's underlying business trends, allowing for a more focused evaluation of operational efficiency and profitability by excluding certain one-off or non-recurring items.

Key Highlights

  • 1Abbott Laboratories filed an 8-K on April 22, 2015, to report its Q1 2015 financial results.
  • 2The filing incorporates a press release (Exhibit 99.1) containing the detailed Q1 2015 earnings announcement.
  • 3Abbott utilized non-GAAP financial measures in its Q1 2015 earnings report.
  • 4Non-GAAP measures exclude items such as cost reduction initiatives, transaction-related costs, and tax expenses from one-time foreign earnings repatriation.
  • 5Intangible amortization expense is also excluded from Abbott's non-GAAP financial measures.
  • 6The company believes these non-GAAP measures offer better visibility into ongoing business performance and are used internally for management assessment.
  • 7Investors are cautioned to consider non-GAAP measures in addition to, and not as a substitute for, GAAP financial measures.

Frequently Asked Questions

The main purpose of this 8-K filing is to report Abbott Laboratories' financial results for the first quarter of 2015 and to make the accompanying press release publicly available.

Non-GAAP financial measures are financial metrics that exclude certain items from GAAP (Generally Accepted Accounting Principles) figures. Abbott uses them to provide investors with a clearer view of ongoing business performance by excluding items that may be unusual or unpredictable, such as restructuring costs or one-time tax events. They are also used internally by management to assess performance.

According to the filing, Abbott's non-GAAP measures for Q1 2015 exclude cost reduction initiatives, transaction-related costs, tax expense associated with a one-time repatriation of ex-U.S. earnings, and intangible amortization expense.

The specific financial figures for the first quarter of 2015 are detailed in the press release dated April 22, 2015, which is furnished as Exhibit 99.1 to this 8-K filing and incorporated by reference.